http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010311084-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5edde3db28268dc748d2dab8e10ab06 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-485 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2010-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0afeae53a21e03bc3d15f567b35da9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c3b7ddfe3b4234677be52ad03858acd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba01700785c6a559e4a6f98dc27dbc39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f935b2427335dec3b5def043e508345f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e519e238811e68b6eace6a65a2977fb0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2480ec12a4c20ddf8150ad0dcde14740 |
| publicationDate | 2010-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2010311084-A1 |
| titleOfInvention | Methods for predicting a patient's response to egfr inhibitors |
| abstract | The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to a monoclonal EGFR antibody, such as cetuximab. The method generally comprises culturing malignant cells from a patient's specimen (e.g., biopsy specimen), contacting the cultured cells with a monoclonal EGFR antibody that is a candidate treatment for the patient, and evaluating the cultured cells for a response to the drug. In certain embodiments, monolayer(s) of malignant cells are cultured from explants prepared by mincing tumor tissue, and the cells of the monolayer are suspended and plated for chemosenstivity testing. The in vitro response to the drug as determined by the method of the invention is correlative with the patient's in vivo response upon receiving the monoclonal EGFR antibody during chemotherapeutic treatment (e.g., in combination with other standardized or individualized chemotherapeutic regimen). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014303103-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10078090-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3604551-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10195174-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011238322-A1 |
| priorityDate | 2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 181.